Mitochondrial health has become one of the biggest conversations in longevity medicine.
That makes sense. Mitochondria help our cells turn nutrients into usable energy, and their function can change as we age. Researchers are increasingly interested in whether supporting the body's ability to maintain healthy mitochondria could influence muscle function, immune health, metabolic health, and other aspects of aging.
One compound getting significant attention is urolithin A.
A new randomized clinical trial published October 9, 2026, in JAMA Network Open examined urolithin A in middle-aged adults with obesity. The study did not improve its primary measure of blood-vessel function, but researchers did observe changes in the brain's blood-oxygen response during a working-memory task. Participants did not actually perform better on the memory task.
If we looked only at this new study, it might be easy to conclude that urolithin A has limited effects.
But that would miss the larger body of research.
Previous randomized human trials have found improvements in muscle endurance and strength, changes in markers associated with mitochondrial health, and increases in proteins involved in mitophagy. More recent research has also begun exploring whether urolithin A may influence aspects of immune aging.
So what does urolithin A actually do, and how strong is the evidence? The answer is promising, but nuanced.
First, What Is Urolithin A?
Urolithin A is a compound that can be produced in the gut after we eat foods containing substances called ellagitannins and ellagic acid. These compounds are found in foods such as pomegranates, walnuts, and some berries. But there is an interesting catch: not everyone produces urolithin A equally well.
The conversion depends partly on the composition of the gut microbiome, meaning the collection of microorganisms living in the digestive tract. Some people produce meaningful amounts of urolithin A after eating these foods, while others produce very little.
This variability is one reason researchers have studied urolithin A directly as a supplement.
The main biological process attracting attention is mitophagy.
What Is Mitophagy?
Your mitochondria are constantly working. Like other parts of the cell, they can become damaged or less efficient over time. The body has quality-control systems that identify damaged mitochondria, remove them, and recycle their components. This process is called mitophagy.
You can think of it as cellular housekeeping for mitochondria. The goal is not simply to have more mitochondria. Cells need functioning mitochondria and an effective way to clear out ones that are no longer working properly.
Research in animals and laboratory models has shown that urolithin A can activate pathways involved in mitophagy. Human studies have also demonstrated changes in certain mitochondrial and mitophagy-related biomarkers after supplementation.
But improving a biological marker is not the same thing as improving someone's health. That is why clinical trials matter.
What Have Human Studies Found for Muscle?
This is where some of the stronger human evidence exists.
A randomized clinical trial published in JAMA Network Open studied 66 adults between ages 65 and 90. Participants received either 1,000 mg of urolithin A daily or placebo for four months.
The people taking urolithin A showed significant improvements in muscle endurance, meaning their hand and leg muscles could perform more repeated contractions before fatigue.
Researchers also found reductions in several blood markers associated with mitochondrial metabolism and inflammation.
But not every outcome improved.
Urolithin A did not significantly outperform placebo on the study's main six-minute walking endpoint or on its measure of maximal ATP production. That is important because it shows why we should avoid reducing a study to either “it worked” or “it didn't." Some measures improved. Others did not.
What About Middle-Aged Adults?
Another randomized trial studied urolithin A in middle-aged adults for four months.
Researchers reported roughly 12% improvement in certain measures of muscle strength with supplementation. They also observed changes in proteins related to mitophagy and mitochondrial metabolism in skeletal muscle.
There were encouraging signals in aerobic endurance and physical performance as well. But again, the study did not meet its primary endpoint, which was improvement in peak power output. That makes the result encouraging rather than definitive.
Taken together, these trials suggest that urolithin A may have an effect on muscle endurance, strength, and biological markers related to mitochondrial health. They do not establish that it dramatically improves overall physical performance in everyone.
What Does the Larger Evidence Say?
A 2024 systematic review looked at five human studies including 250 participants.
The review found that urolithin A was associated with increases in muscle strength and endurance, reductions in some inflammatory markers, and changes in genes or proteins involved in mitochondrial health, autophagy, and fatty-acid metabolism.
At the same time, the review did not find clear evidence of benefits for body composition, cardiovascular outcomes, or overall physical function.
That is probably the most accurate way to think about urolithin A right now. There are real biological signals and encouraging human findings. But we are not yet looking at a supplement that has been proven to slow aging, prevent disease, or broadly improve longevity outcomes.
What About Immune Aging?
This is one of the newer and more interesting areas of research.
A randomized, placebo-controlled trial in 50 healthy middle-aged adults examined whether four weeks of urolithin A could affect immune-cell biology.
Researchers found changes in several immune-cell populations and functions, including an increase in more naive-like CD8 T cells and improvements in fatty-acid oxidation within those cells. They also reported increases in mitochondrial biogenesis in CD8 cells and changes in certain natural killer cells and monocytes.
Why is that interesting?
As we age, the immune system can gradually become less adaptable. Some immune cells become more exhausted or less metabolically flexible, while chronic low-grade inflammatory signaling may increase.
Researchers sometimes refer to aspects of this process as immunosenescence and inflammaging.
The study suggests urolithin A may influence some of these biological processes.
But this is still mechanistic research. The study did not show that people taking urolithin A got fewer infections, avoided disease, or lived longer. Those clinical outcomes would require much larger and longer studies.
And What Did the New Brain and Blood-Vessel Study Find?
This brings us back to the October 9 study.
Researchers enrolled 50 adults ages 40 to 64 with obesity and randomized them to receive 1,000 mg of urolithin A daily or placebo for four weeks.
The study's main goal was to see whether urolithin A improved endothelial function.
The endothelium is the thin layer of cells lining blood vessels. It helps regulate how blood vessels expand and contract and is important for cardiovascular health.
Urolithin A did not significantly improve the primary measure of peripheral endothelial function compared with placebo.
The researchers also measured how blood oxygenation in the brain changed during a working-memory task. They found a greater task-related blood-oxygen response in certain brain regions, particularly an area of the prefrontal cortex involved in working memory. But participants did not perform better on the cognitive task.
So this study does not show that urolithin A improves memory. It suggests there may be an effect on cerebrovascular response that deserves further investigation.
Why Mixed Results Are Not Necessarily Bad Science
Longevity research is full of compounds that look powerful in animal or cellular studies and then produce much smaller effects in humans. That is normal.
Human aging is incredibly complex. Improving mitophagy does not automatically translate into stronger muscles. Improving a mitochondrial biomarker does not necessarily improve walking speed. Changing an immune-cell population does not automatically prevent illness. And changing blood flow in the brain during a task does not necessarily improve cognition. Each step requires evidence.
This is why the evolving urolithin A research is actually interesting. We now have several human trials asking increasingly specific questions about what happens when this biological pathway is targeted. The answers are not uniformly positive, but they are beginning to form a pattern.
What Seems Most Promising Right Now?
Based on the human research so far, the most consistent signal appears to involve mitochondrial biology and muscle. Randomized trials have found improvements in certain measures of muscle endurance and strength, along with changes in biological markers related to mitochondrial function and mitophagy.
There are also early signals involving inflammatory markers and immune-cell function. The evidence is less convincing for cardiovascular function. And we do not currently have evidence that urolithin A prevents cognitive decline, dementia, cardiovascular disease, or other major age-related conditions. We also do not have evidence that it extends human lifespan.
Mitochondrial Health Is Bigger Than a Supplement
This is perhaps the most important point. Urolithin A is interesting because it helps researchers study a biological pathway that becomes increasingly relevant as we age. But mitochondrial health is not something that comes from one capsule.
Exercise is one of the most powerful known stimulators of mitochondrial adaptation.
Sleep, metabolic health, nutrition, cardiovascular fitness, and physical activity all influence cellular energy systems.
At Jyzen, when someone is struggling with fatigue, exercise recovery, metabolic changes, or declining physical capacity, we are not interested only in whether they should take a mitochondrial supplement.
We want to understand the larger physiology: How is cardiovascular fitness? How is body composition changing? Is metabolic health shifting? How is the person sleeping? Are hormones contributing? Are nutritional needs being met? What does their exercise response look like? Does their medical history point toward something else entirely?
A supplement may be one tool, but it should not replace understanding the person.
Should Everyone Take Urolithin A?
The current evidence does not support saying everyone should take it. Short-term clinical trials have generally found urolithin A to be well tolerated, but most studies have been relatively small and have lasted only weeks or months. We still need larger studies, longer follow-up, more diverse populations, and clearer evidence of clinically meaningful outcomes.
There is also a difference between studying a standardized compound in a clinical trial and assuming that every supplement sold commercially will produce the same result. For someone considering urolithin A, factors such as overall health, medications, goals, diet, and medical history still matter.
The Bigger Longevity Question
The excitement around urolithin A reflects a larger shift in longevity medicine.
Researchers are increasingly asking whether we can intervene in some of the biological processes that change with aging rather than waiting for disease to appear. Mitochondrial quality control is one of those processes.
The human evidence around urolithin A is encouraging enough to keep studying. It suggests possible benefits for muscle endurance and strength and measurable effects on mitochondrial and immune biology. But it is not yet evidence of an anti-aging therapy.
At Jyzen, we believe the goal is not to chase every promising molecule. It is to understand which interventions are supported by meaningful evidence, which ones may make sense for the individual, and whether they are actually changing the outcome we care about. Because longevity medicine should not be about taking more things.
It should be about understanding your biology well enough to make better decisions. And earlier understanding creates more choices.
This article is for educational purposes only and is not individualized medical advice. Urolithin A is not established as a treatment for cognitive decline, cardiovascular disease, immune dysfunction, or aging itself. Supplement decisions should be considered in the context of individual health, medications, goals, and appropriate clinical guidance.
Primary New Study
da Costa Pinaffi-Langley AC, Gulej R, Kaposzta Z, et al. Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity: A Randomized Clinical Trial. JAMA Network Open. Published October 9, 2026.
Supporting Human Research
Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022.
Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022.
Targeting aging with urolithin A in humans: A systematic review. Ageing Research Reviews. 2024.